Get started
Work

Comparison of Intratympanic Oxytocin and Dexamethasone in Cisplatin Ototoxicity: An Experimental Study

Year: 2024
Type: article
Abstract: Purpose: In this study, we aimed to investigate the efficacy of intratympanic resveratrol and intratympanic dexamethasone treatment in cisplatin-induced ototoxicity. We also compared intratympanic atosiban (oxytocin antagonist) and oxytocin in cisplatin ototoxicity. Methods: In this study, 30 rats (60 ears) were used by separating into 5 groups. Cisplatin was administered intraperitoneally to the first group (n=6). On the second group (n=6), oxytocin were administered intratympanically. On the third group (n=6), dexamethasone were administered intratympanically. On the fourth group (n=6), atosiban were administered intratympanically. On the fifth group (n=6), 0.9% NaCl were administered intratympanically. In Groups 2, 3, 4 and 5, cisplatin was given 30 minute after the administration of medication. ABR and DPOAE tests were performed on all groups before and 72 h after the procedure. Results: The post-treatment ABR I, ABR IV and ABR threshold values of the groups were found to be significantly higher than the pre-treatment values (p<0.001). There was no significant prolongation of the post-treatment ABR I-IV interval in the oxytocin and dexamethasone groups (p>0.05). Pre-treatment values were higher than post-treatment values in all groups. There was no significant decrease in the frequencies of 2832 and 4004 after treatment in the oxytocin and dexamethasone group compared to pre-treatment. No difference was found between the oxytocin and dexamethasone groups (p>0.05). Conclusion: As a result, it has been shown that intratympanic oxytocin may be an option that can be used in the treatment, although it is not as effective as dexamethasone in preventing cisplatin ototoxicity.
DOI: 10.1007/s12070-024-04701-z
Language: English
Subfield: Sensory Systems
Open Access status: green
OpenAlex ID: W4395072356
FWCI: 0.237
Cites: 24
Cited by: 1
Related to: 10